lysergic acid diethylamide has been researched along with Atrophy in 1 studies
Lysergic Acid Diethylamide: Semisynthetic derivative of ergot (Claviceps purpurea). It has complex effects on serotonergic systems including antagonism at some peripheral serotonin receptors, both agonist and antagonist actions at central nervous system serotonin receptors, and possibly effects on serotonin turnover. It is a potent hallucinogen, but the mechanisms of that effect are not well understood.
lysergic acid diethylamide : An ergoline alkaloid arising from formal condensation of lysergic acid with diethylamine.
Atrophy: Decrease in the size of a cell, tissue, organ, or multiple organs, associated with a variety of pathological conditions such as abnormal cellular changes, ischemia, malnutrition, or hormonal changes.
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (100.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Campbell, AM | 1 |
Evans, M | 1 |
Thomson, JL | 1 |
Williams, MJ | 1 |
1 other study available for lysergic acid diethylamide and Atrophy
Article | Year |
---|---|
Cerebral atrophy in young cannabis smokers.
Topics: Adolescent; Adult; Amphetamines; Atrophy; Brain Diseases; Cerebral Ventricles; Cerebral Ventriculogr | 1971 |